Close Menu

NEW YORK – The GenomeWeb Index fell 4 percent in August, despite a continued rise in the broader markets and what had been several months of gains for shares of firms in the omics tools and molecular diagnostics sectors.

The index underperformed the Dow Jones Industrial Average, the Nasdaq, and the Nasdaq Biotechnology Index, which rose nearly 8 percent, nearly 10 percent, and nearly 1 percent, respectively. Individual stock performances in the GenomeWeb Index were mixed in August, as 19 of the 32 stocks saw gains and 13 saw losses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.